These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20950464)

  • 1. What differences are detected by superiority trials or ruled out by noninferiority trials? A cross-sectional study on a random sample of two-hundred two-arms parallel group randomized clinical trials.
    Gayet-Ageron A; Agoritsas T; Combescure C; Bagamery K; Courvoisier DS; Perneger TV
    BMC Med Res Methodol; 2010 Oct; 10():93. PubMed ID: 20950464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninferiority trials with nonadherence to the assigned randomized treatment.
    Korn EL; Gray RJ; Freidlin B
    Clin Trials; 2019 Dec; 16(6):673-681. PubMed ID: 31409130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of the noninferiority margin in clinical trials was driven by baseline risk, type of primary outcome, and benefits of new treatment.
    Gayet-Ageron A; Agoritsas T; Rudaz S; Courvoisier D; Perneger T
    J Clin Epidemiol; 2015 Oct; 68(10):1144-51. PubMed ID: 25716902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials.
    Vavken P
    Clin Orthop Relat Res; 2011 Sep; 469(9):2645-53. PubMed ID: 21246313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating equivalence and noninferiority trials.
    Dasgupta A; Lawson KA; Wilson JP
    Am J Health Syst Pharm; 2010 Aug; 67(16):1337-43. PubMed ID: 20689122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011.
    Doshi P; Hur P; Jones M; Albarmawi H; Jefferson T; Morgan DJ; Spears PA; Powers JH
    JAMA Intern Med; 2017 Oct; 177(10):1452-1459. PubMed ID: 28828473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E; Tango T
    J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment.
    Moroz V; Wilson JS; Kearns P; Wheatley K
    Trials; 2014 Dec; 15():481. PubMed ID: 25490968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
    Piaggio G; Elbourne DR; Altman DG; Pocock SJ; Evans SJ;
    JAMA; 2006 Mar; 295(10):1152-60. PubMed ID: 16522836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial design for assessing noninferiority when superiority is expected.
    Freidlin B; Korn EL; George SL; Gray R
    J Clin Oncol; 2007 Nov; 25(31):5019-23. PubMed ID: 17971602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality.
    Gomberg-Maitland M; Frison L; Halperin JL
    Am Heart J; 2003 Sep; 146(3):398-403. PubMed ID: 12947355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designs of superiority and noninferiority trials for binary responses are noninterchangeable.
    Hilton JF
    Biom J; 2006 Dec; 48(6):934-47. PubMed ID: 17240653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies.
    Oczkowski SJ
    Open Med; 2014; 8(2):e67-72. PubMed ID: 25009686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A U-statistics based approach to sample size planning of two-arm trials with discrete outcome criterion aiming to establish either superiority or noninferiority.
    Wellek S
    Stat Med; 2017 Feb; 36(5):799-812. PubMed ID: 27878839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio.
    Hida E; Tango T
    Pharm Stat; 2018 Sep; 17(5):489-503. PubMed ID: 29984524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children.
    Krysan DJ; Kemper AR
    Pediatr Infect Dis J; 2002 Aug; 21(8):753-8. PubMed ID: 12192164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
    Hussain M; Tangen C; Higano C; Vogelzang N; Thompson I
    J Clin Oncol; 2016 Jan; 34(3):280-5. PubMed ID: 26552421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.